NCT02213315View on ClinicalTrials.gov

A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Healthy Volunteers
Interventions
DRUG

100mg Mavrilimumab

100mg Mavrilimumab

DRUG

150mg mavrilimumab

150mg mavrilmumab

OTHER

Placebo

Placebo

Trial Locations (1)

Unknown

Research Site, London

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT02213315 - A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects | Biotech Hunter | Biotech Hunter